(AVNT) Avient - Overview
Stock: Colorants, Additives, Inks, Polymers, Formulations
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.12% |
| Yield on Cost 5y | 2.90% |
| Yield CAGR 5y | 5.46% |
| Payout Consistency | 68.9% |
| Payout Ratio | 53.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 31.4% |
| Relative Tail Risk | -8.17% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.07 |
| Alpha | -26.09 |
| Character TTM | |
|---|---|
| Beta | 1.351 |
| Beta Downside | 1.321 |
| Drawdowns 3y | |
|---|---|
| Max DD | 46.87% |
| CAGR/Max DD | 0.08 |
Description: AVNT Avient January 12, 2026
Avient Corp (NYSE:AVNT) is a global material-solutions provider operating in two segments: Color, Additives & Inks, which supplies custom concentrates, dispersions and proprietary inks for a broad range of end-markets; and Specialty Engineered Materials, which delivers polymer formulations and processing services for thermoplastics. The company serves diversified industries-including medical devices, food packaging, transportation, construction, and apparel-through a mix of direct sales, distributors, and commissioned agents. Formerly PolyOne, Avient rebranded in June 2020 and traces its roots to 1885, with headquarters in Avon Lake, Ohio.
Key recent metrics: FY 2023 revenue was $2.33 billion, up 3.2% YoY, while adjusted EBITDA margin held at ~9%, reflecting stable pricing power in specialty chemicals. The segment’s growth is buoyed by rising demand for sustainable packaging solutions and regulatory-driven shifts toward low-VOC inks, both of which are projected to expand at 5-6% CAGR through 2028. Avient’s balance sheet shows net cash of $210 million and a debt-to-EBITDA ratio of 2.4×, indicating moderate leverage relative to peers.
If you want a more granular, data-driven valuation, the ValueRay platform offers a comprehensive model that can help you test these assumptions further.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 113.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.21 > 1.0 |
| NWC/Revenue: 22.25% < 20% (prev 17.52%; Δ 4.73% < -1%) |
| CFO/TA 0.04 > 3% & CFO 256.4m > Net Income 113.3m |
| Net Debt (1.53b) to EBITDA (400.6m): 3.81 < 3 |
| Current Ratio: 2.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (91.8m) vs 12m ago -0.22% < -2% |
| Gross Margin: 32.21% > 18% (prev 0.31%; Δ 3189 % > 0.5%) |
| Asset Turnover: 53.64% > 50% (prev 53.13%; Δ 0.51% > 0%) |
| Interest Coverage Ratio: 2.02 > 6 (EBITDA TTM 400.6m / Interest Expense TTM 119.4m) |
Altman Z'' 2.56
| A: 0.12 (Total Current Assets 1.42b - Total Current Liabilities 701.6m) / Total Assets 6.06b |
| B: 0.31 (Retained Earnings 1.87b / Total Assets 6.06b) |
| C: 0.04 (EBIT TTM 241.4m / Avg Total Assets 6.05b) |
| D: 0.48 (Book Value of Equity 1.76b / Total Liabilities 3.67b) |
| Altman-Z'' Score: 2.56 = A |
Beneish M -3.04
| DSRI: 1.03 (Receivables 484.5m/465.1m, Revenue 3.25b/3.21b) |
| GMI: 0.97 (GM 32.21% / 31.31%) |
| AQI: 1.01 (AQ_t 0.60 / AQ_t-1 0.60) |
| SGI: 1.01 (Revenue 3.25b / 3.21b) |
| TATA: -0.02 (NI 113.3m - CFO 256.4m) / TA 6.06b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of AVNT shares?
Over the past week, the price has changed by +7.22%, over one month by +17.49%, over three months by +29.60% and over the past year by -6.22%.
Is AVNT a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AVNT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 41.8 | 7.7% |
| Analysts Target Price | 41.8 | 7.7% |
| ValueRay Target Price | 43 | 10.9% |
AVNT Fundamental Data Overview February 03, 2026
P/E Forward = 12.0048
P/S = 1.0197
P/B = 1.3898
P/EG = 1.2003
Revenue TTM = 3.25b USD
EBIT TTM = 241.4m USD
EBITDA TTM = 400.6m USD
Long Term Debt = 1.97b USD (from longTermDebt, last quarter)
Short Term Debt = 500.0k USD (from shortTermDebt, last quarter)
Debt = 1.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.53b USD (from netDebt column, last quarter)
Enterprise Value = 4.84b USD (3.31b + Debt 1.97b - CCE 445.6m)
Interest Coverage Ratio = 2.02 (Ebit TTM 241.4m / Interest Expense TTM 119.4m)
EV/FCF = 32.01x (Enterprise Value 4.84b / FCF TTM 151.1m)
FCF Yield = 3.12% (FCF TTM 151.1m / Enterprise Value 4.84b)
FCF Margin = 4.65% (FCF TTM 151.1m / Revenue TTM 3.25b)
Net Margin = 3.49% (Net Income TTM 113.3m / Revenue TTM 3.25b)
Gross Margin = 32.21% ((Revenue TTM 3.25b - Cost of Revenue TTM 2.20b) / Revenue TTM)
Gross Margin QoQ = 30.37% (prev 32.07%)
Tobins Q-Ratio = 0.80 (Enterprise Value 4.84b / Total Assets 6.06b)
Interest Expense / Debt = 1.68% (Interest Expense 33.2m / Debt 1.97b)
Taxrate = 23.54% (10.1m / 42.9m)
NOPAT = 184.6m (EBIT 241.4m * (1 - 23.54%))
Current Ratio = 2.03 (Total Current Assets 1.42b / Total Current Liabilities 701.6m)
Debt / Equity = 0.83 (Debt 1.97b / totalStockholderEquity, last quarter 2.37b)
Debt / EBITDA = 3.81 (Net Debt 1.53b / EBITDA 400.6m)
Debt / FCF = 10.10 (Net Debt 1.53b / FCF TTM 151.1m)
Total Stockholder Equity = 2.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.87% (Net Income 113.3m / Total Assets 6.06b)
RoE = 4.85% (Net Income TTM 113.3m / Total Stockholder Equity 2.34b)
RoCE = 5.60% (EBIT 241.4m / Capital Employed (Equity 2.34b + L.T.Debt 1.97b))
RoIC = 4.23% (NOPAT 184.6m / Invested Capital 4.37b)
WACC = 7.31% (E(3.31b)/V(5.28b) * Re(10.89%) + D(1.97b)/V(5.28b) * Rd(1.68%) * (1-Tc(0.24)))
Discount Rate = 10.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.05%
[DCF Debug] Terminal Value 80.81% ; FCFF base≈156.1m ; Y1≈157.2m ; Y5≈168.9m
Fair Price DCF = 20.80 (EV 3.43b - Net Debt 1.53b = Equity 1.90b / Shares 91.6m; r=7.31% [WACC]; 5y FCF grow 0.29% → 2.90% )
EPS Correlation: -10.88 | EPS CAGR: 5.14% | SUE: 0.0 | # QB: 0
Revenue Correlation: -48.32 | Revenue CAGR: -10.08% | SUE: -0.90 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.81 | Chg30d=-0.010 | Revisions Net=-3 | Analysts=5
EPS next Year (2026-12-31): EPS=3.05 | Chg30d=-0.006 | Revisions Net=-2 | Growth EPS=+8.5% | Growth Revenue=+2.4%